Momenta Pharmaceuticals, Inc. - News/Events - Press Releases

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

12/24/2019

Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference

12/13/2019

Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors

12/12/2019

Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock

12/10/2019

Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

11/07/2019

Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition

11/06/2019

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

10/31/2019

Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results

10/17/2019

Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast

09/19/2019

Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

08/02/2019

Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results

08/01/2019

Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

07/30/2019

Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

07/19/2019

Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast

06/19/2019

Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation

06/04/2019

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference

05/09/2019

Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference

05/02/2019

Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results

04/18/2019

Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast

03/28/2019

Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

03/21/2019

Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta

02/22/2019

Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

02/08/2019

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast

02/07/2019

Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting

01/29/2019

Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G

01/02/2019

Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference